The Analytical Pharmacology Core (APC) encourages and facilitates collaborative research between basic scientists and clinicians by providing a wide range of analytical and consultative services in a GLP-capable environment. The APC assists with the design and conduct of pharmacokinetic, pharmacodynamic, and biomarker correlative studies for clinical and preclinical investigations of small molecules, biologic agents (e.g. antibodies, antisense oligonucleotides, vaccines, and cellular therapeutics).
Primary services provided are;
  1. quantitative assay development and sample analysis (LC-MS/MS, ICP-MS, GC/MS, HPLC, Luminex, ELISA, QPCR) of drugs, biomarkers, and related compounds; and
  2. study design and expert analysis of pharmacokinetic and biomarker data. The APC is located in the Shapiro Building. The most heavily utilized major equipment within the core are the LC-MS/MS instruments and the FLEXMAP 3D multiplex immunoassay platform. Mass spectrometry instrumentation includes a Micromass Quattro Ultima triple quad, a Waters Quattro Premier XE triple quad, a Sciex QTRAP 5500, an Agilent 6410, and a recently acquired Waters Xevo-TQXS. Each of these instruments includes different HPLC front-end components with unique features that provide greater flexibility, and all of the systems provide state-of-the-art selectivity and sensitivity for analytes in complex biological matrices. Additional key core equipment includes an Agilent 8800 inductively-coupled plasma triple quadrupole mass spectrometer (ICP-MS) for determination of metals and metal containing compounds, and four complete HPLC systems.
For analysis of biological and cellular agents, the Core has a FLEXMAP 3D Bioplex instrument for multiplex immunoassays, a Bio-Rad QX200 Droplet Digital PCR for absolute quantitation of gene expression, a FLUOstar OPTIMA multi-label plate reader for a wide range of high-throughput ELISA applications, and a Guava PCA-96 analytical cell analyzer.
The core is directed by Dr. Timothy Synold, Professor in the Department of Cancer Biology, who also serves as the Scientific Leader of the Phase I Clinical Trials Disease Team, and Associate Chair of the Cancer Protocol Review and Monitoring Committee.